
Lyophilized peptide powder is a peptide formulation that was frozen as a solution and then dried under vacuum so that its water leaves as vapor from ice instead of evaporating from liquid. The technique is lyophilization, also called freeze-drying: a low-temperature dehydration process in which the product is frozen and the pressure lowered, removing ice by sublimation. What remains is a porous solid, often a cake rather than a loose powder, with microscopic gaps left by the ice crystals.[1]
The point of making the solid is stability. Proteins often have to be converted into solid forms to reach an acceptable shelf life, and lyophilization is a common method for doing so. It also brings its own freezing and drying stresses, which can denature a protein to varying degrees.[2] A dry formulation is therefore not simply the original solution with its water missing: its structure and stability also depend on what happened during the cycle.
The Physical Basis: Triple Point and Sublimation
Sublimation is the passage from solid to gas without an intervening liquid phase. Water’s triple point is the temperature and pressure combination at which solid, liquid and gas phases coexist. Freeze-drying combines a frozen product with reduced pressure so that ice can leave by sublimation rather than first melting. During primary drying, heat supplies the energy needed for that change of state.[1]
Because ice crystals occupy volume and then disappear, the dried solid contains microscopic pores. These gaps provide the structure that makes freeze-dried material comparatively easy to rehydrate. The porous cake is thus a consequence of removing ice, not simply a powder compressed into the shape of a vial.[1]
The Four Stages of a Freeze-Drying Cycle

A complete process has four stages: pretreatment, freezing, primary drying and secondary drying.[1]
Pretreatment. This establishes the starting solution before freezing. For sterile parenteral products, the process described includes solution preparation, multi-step filtration and filling into final containers under sterile conditions. Freeze-drying itself is not a sterility guarantee; those microbial controls are separate from the water-removal step.[1]
Freezing. The solution is cooled to form ice. Larger ice crystals create a network that allows water vapor to escape more readily during sublimation. Slow freezing or an annealing step can promote their growth.[1] Annealing is an optional controlled temperature hold after initial freezing; its purpose is to change the frozen structure before drying, rather than to remove the remaining water.
Primary drying. Pressure is lowered and enough heat is supplied for the ice to sublimate. Most of the water leaves during this phase; the general process overview describes roughly 95% removal at this stage.[1]
Secondary drying. This phase removes unfrozen water molecules remaining after the ice is gone. Water removal now depends on desorption rather than sublimation of ice, so completing primary drying does not mean that the material has reached its final moisture content.[1]
Why the Freezing Step Decides the Rest
The freezing step affects sample morphology, the physical state of the product, residual moisture, reconstitution time and the performance of both drying phases. Its influence persists after the ice itself has disappeared.[3]
Ice formation and the temperature at which the matrix loses structure are related process concerns, but they are not interchangeable. In experiments with trehalose-containing cell-culture-medium solutions, ice seeding changed ice-crystal morphology and therefore drying rate, while the seeding conditions tested had negligible effect on collapse temperature.[4] Changing the pore-forming ice network need not change the temperature limit of the surrounding formulation.
Critical Temperature, Glass Transition, and Collapse

For a crystalline mixture, the eutectic temperature describes melting of that mixture. An amorphous freeze-concentrated phase instead has a glass transition temperature, Tg′, associated with its change from a rigid glass to a more mobile state. The macroscopic collapse temperature, Tc, is the temperature above which the product loses its overall structure during lyophilization; it usually sits a few degrees above Tg′. These temperatures help define the thermal limits for drying a particular formulation.[5]
Collapse temperature can be measured by freeze-drying microscopy. In simple water–trehalose solutions, it was similar to the glass transition temperature of the maximally freeze-concentrated phase, but adding cell-culture-medium components changed that relationship and the measured collapse temperature.[4] The composition matters, not just the presence of a familiar sugar.
Thermal measurements also need not predict visible collapse equally well in every system. In experiments with catalase, beta-galactosidase and lactate dehydrogenase without protective solutes, differential scanning calorimetry predicted collapse onset only for beta-galactosidase. For the other proteins, either no Tg′ transition was observed or the apparent glass transition did not correlate with the collapse seen microscopically.[6]
Glass formation is not the whole explanation for stability either. In IgG1 antibody and recombinant human serum albumin formulations, storage stability correlated with retention of native protein structure during drying. Stabilization by sugars could not be explained wholly by glass dynamics.[7] Maintaining cake structure and preserving the molecule are related goals, but one measurement does not describe both.
Excipients: What Sucrose, Trehalose, and Mannitol Do
A freeze-dried peptide formulation may contain excipients as well as peptide. Protectants help limit damage during freezing, drying and storage; bulking agents primarily support the solid’s structure. These functions can call for different ingredients rather than a single additive that performs every role.[2][5]
Sucrose and trehalose act as protectants. In the IgG1 and albumin experiments, both outperformed sorbitol, which only slightly protected against aggregation and had no effect on chemical degradation. Chemical degradation and aggregation rates decreased as the sucrose-to-protein weight ratio increased from zero to 2:1.[7] These comparisons show why sugar identity and proportion matter to formulation development.
Mannitol is commonly used as a crystalline bulking agent. In experiments with insulin and glucagon, mannitol-containing formulations produced the most intact and elegant cakes, yet its crystallization correlated with reduced long-term stability of both model polypeptides.[8] Better cake support did not necessarily mean better molecular preservation.
Crystalline bulking agents can support cake structure and raise macroscopic collapse temperature, but typically do not provide the protection of an amorphous stabilizing matrix. Mannitol hydrate can also release water into the amorphous phase during storage, potentially compromising stability.[5] Combining a crystalline bulking agent with an amorphous protectant can balance drying efficiency and cake structure against long-term stability; the balance depends on their proportions.[8]
Residual Moisture Is a Formulation Property
Lyophilized does not mean completely water-free. The general freeze-drying overview describes a final residual water content around 1–4%, but that range is not a specification for every peptide formulation.[1] Secondary drying sets the remaining moisture after ice removal, and the amount has to be considered alongside stability rather than treated as an isolated target.
Lower is not automatically better in every system. In the three-protein study without protective solutes, activity recovery dropped sharply at residual moisture levels below about 10%.[6] That observation is not a recommended moisture level for peptide powders; it demonstrates why a moisture target must be tied to the formulation and the outcome being measured. Conversely, collapsed formulations lacking structural excipients in the insulin and glucagon study had higher residual moisture because the loss of open channels hindered water-vapor escape.[8]
Storage Behavior: Assay Loss and Particle Formation
Freeze-drying can improve storage stability; it does not stop change. Even a successfully lyophilized protein formulated with stabilizer may still have limited long-term stability.[2]
A secretin formulation illustrates the changes that analytical measurements can reveal. Lyophilized samples were stored at −20 °C, 4 °C, 25 °C and 25 °C/60% relative humidity, then analyzed over eight weeks. Reversed-phase HPLC showed decreased secretin concentration by week eight. At 25 °C/60% relative humidity, particles detected after reconstitution grew from about 390 nm initially to more than 2 µm as early as week one. Reconstitution time increased from about 20 seconds initially to about 67 seconds at week eight. Mannitol also underwent polymorphic transitions and became more crystalline during storage.[9]
Assay loss, particle growth and changing solid-state structure describe different aspects of the same formulation’s aging. Together they show why environmental conditions and excipient behavior matter after drying has finished.[9]
These findings concern physicochemical, analytical and laboratory model-protein or polypeptide studies, not animal or human outcomes. They explain formulation behavior without establishing clinical effects or a universal shelf life for peptide powders.
Cake Appearance Is a Process Signature, Not an Identity Test
A uniform, elegant cake is a visual ideal, but a non-ideal cake can be an inherent characteristic of the formulation, container presentation or process without necessarily compromising product quality. Appearance acceptance criteria therefore need to be specific to the product and based on science and risk.[10]
Appearance alone does not establish peptide identity or purity. Nor can shrinkage by itself reconstruct the temperature history: cake observations have to be interpreted alongside the formulation’s thermal behavior, moisture measurements and stability results.[5][10]
Related research: Peptide Reconstitution for Laboratory Research; Peptide Stability Claims and Batch-Specific Evidence; How to Read a Research Peptide COA.
Research Use Only Disclaimer: This article is for laboratory research and analytical education only. It is not a validated experimental protocol or medical or veterinary advice. Research materials are not for administration to humans or animals.
References
- Freeze drying — Wikipedia
- Lyophilization and development of solid protein pharmaceuticals — Wang, 2000
- The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals — Kasper and Friess, 2011
- Collapse temperature of solutions important for lyopreservation of living cells at ambient temperature — Yang et al., 2010
- Practical advice in the development of a lyophilized protein drug product — Cheng et al., 2025
- Effect of process conditions on recovery of protein activity after freezing and freeze-drying — Jiang and Nail, 1998
- Mechanism of protein stabilization by sugars during freeze-drying and storage — Chang et al., 2005
- The Detrimental Effects of Crystalline Excipients: How They Jeopardize the Long-Term Stability of Freeze-Dried Polypeptide Formulations — Gao et al., 2025
- Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin — Srinivasan et al., 2015
- Lyophilized Drug Product Cake Appearance: What Is Acceptable? — Patel et al., 2017